Related Experiment Videos
MUSE therapy: preliminary clinical observations
1Department of Urology, University of California at Los Angeles School of Medicine 90095-1738, USA.
Urology
|December 31, 1997
Summary
Intracavernosal injections are more effective for erectile dysfunction than the transurethral alprostadil system (MUSE). MUSE resulted in fewer rigid erections and more side effects compared to injections.
Area of Science:
- Urology
- Pharmacotherapy
- Sexual Medicine
Background:
- Intracavernosal injections of vasodilators are a primary treatment for erectile dysfunction.
- A transurethral delivery system for alprostadil (MUSE) offers an alternative pharmacotherapy approach.
Purpose of the Study:
- To compare the efficacy and safety of MUSE with intracavernosal injections for erectile dysfunction.
Main Methods:
- One hundred men with erectile dysfunction were treated with MUSE (125–1000 micrograms).
- Patients had prior experience with intracavernosal injections (papavarine, Regitine, prostaglandin E1).
- Erection quality and adverse events were assessed clinically.
Main Results:
- MUSE achieved rigid erections in 7% of patients, with 30% experiencing partial rigidity.
- Intracavernosal injections yielded sustained rigid erections in 49% of patients.
- Adverse events with MUSE included pain (24%), syncope (3%), urethral bleeding (3%), and priapism (1%).
Conclusions:
- Intracavernosal injections demonstrate superior effectiveness in achieving rigid erections compared to MUSE.
- MUSE is less effective and associated with a higher incidence of adverse events for erectile dysfunction treatment.